IVISbrite™ MPO 425 Chemiluminescent Probe in RediJect™ Solution ((XenoLight™ RediJect Inlammation Probe) is an in vivo imaging reagent for monitoring Inflammation. This probe is available in a ready-to-use format and can be conveniently applied to study myeloperoxidase (MPO) activity of activated phagocytes.
For research use only. Not for use in diagnostic procedures.
true false
The IVISbrite MPO 425 Chemiluminescent Probe in RediJect™ Solution enables longitudinal tracking of MPO level and inflammation status, in vivo, in a variety of disease models, including rheumatoid arthritis, acute septic shock, contact hypersensitivity reaction, and neutrophil rich cancers. This reagent comes in a 1 vial size, enough to inject 5 mice (based on 30g/mouse).
| Optical Imaging Classification | Chemiluminescence Imaging |
|---|---|
| Product Brand Name | IVISbrite |
| Quantity in a Package Amount | 5.0 Units |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Arthritis, Inflammation |
| Unit Size | 1 Kit (5 animals) |
XenoLight RediJect Inflammation Probe is a chemiluminescent reagent for monitoring inflammation. This probe is offered in a ready-to-use format and can be conveniently applied to study myeloperoxidase (MPO) activity of activated phagocytes. The RediJect Inflammation Probe will allow for longitudinal tracking of MPO level and inflammation status, in vivo, in a variety of disease models. This probe has been validated in vivo in detecting rheumatoid arthritis and contact hypersensitivity. Given the probe’s peak emission is 425 nm, the signal is significantly attenuated when imaging at depth, posing challenges for detecting inflammation in deep tissues.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.
